Neurobiology of Disease · 2020 · 10 citations · 55 references
Life SciencesNeurologyNeuroscienceMolecular NeurobiologyMolecular NeuroscienceNeurodegenerationMolecular Basis Of NeurodegenerationNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionParkinson DiseaseParkinsonian DisordersCysteamine TherapyInduced Pluripotent Stem CellsMotor PerformanceMotor Performance TestingParkinson Disease PathologyParkinson's Disease ModelsParkinson’s Disease TreatmentTransgenic Mice
A number of publications have reported that cysteamine has significant therapeutic effects on several aspects of Parkinson's disease (PD)-related pathology but none of these studies have evaluated its impact on pathological forms of α-Synuclein (α-Syn), one of the main hallmarks of PD. We therefore tested the efficacy of cysteamine on the Thy1-α-Syn mouse model which over-expresses full-length human wild-type α-Syn. Two-month (early stage disease) and 6-month old (late stage disease) mice and littermate controls were treated daily with cysteamine (20 mg/kg, i.p.) to assess the protective and restorative properties of this compound. After 6 weeks of treatment, animals were tested using a battery of motor tests. Cysteamine-treated transgenic mice displayed significant improvements in motor performance as compared to saline-treated transgenic littermates. Post-mortem readouts revealed a reduction in fibrillation, phosphorylation and total levels of overexpresed human α-Syn. To determine if such outcomes extended to human cells, the benefits of cysteamine were additionally tested using 6-hydroxydopamine (6-OHDA) treated neurons differentiated from induced pluripotent stem cells (iPSCs) derived from a PD patient harbouring a triplication of the SNCA gene. SNCA neurons treated with cysteamine exhibited significantly more intact/healthy neurites than cells treated with 6-OHDA alone. Additionally, SNCA neurons treated with cysteamine in the absence of 6-OHDA showed a trend towards lower total α-Syn levels. Overall, our in vivo and in vitro findings suggest that cysteamine can act as a disease-modifying molecule by enhancing -the survival of dopaminergic neurons and reducing pathological forms of α-Syn.
55
α-Synuclein is phosphorylated in synucleinopathy lesions
Hideo Fujiwara, Masato Hasegawa, Naoshi Dohmae et al. · Nature Cell Biology · 2002 · 2.2K citations
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Yaming Wang, Marina Cella, Kaitlin Mallinson et al. · Cell · 2015 · 1.8K citations · Full text
Sangjune Kim, Seung‐Hwan Kwon, Tae‐In Kam et al. · Neuron · 2019 · 1.4K citations · Full text